Jubilant Ingrevia Limited
NSE: JUBLINGREA BSE: JUBLINGREA
Prev Close
660.05
Open Price
664.95
Volume
165,388
Today Low / High
656.65 / 680.2
52 WK Low / High
462.3 / 885
Range
641 - 709
Prev Close
662.4
Open Price
662.4
Volume
10,803
Today Low / High
656.85 / 679.9
52 WK Low / High
461.7 / 884.95
Range
640 - 708
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 674.95 (target range: 641 - 709), reflecting a change of 14.9 (2.2574%). On the BSE, it is listed at 674.15 (target range: 640 - 708), showing a change of 11.75 (1.77385%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Jubilant Ingrevia Limited Graph
Jubilant Ingrevia Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Jubilant Ingrevia Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 674.95, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 674.15 | 680.89 | 612.80 - 748.98 |
| 687.63 | 550.11 - 825.16 | ||
| 694.37 | 486.06 - 902.69 | ||
| Bearish Scenario | 674.15 | 667.41 | 600.67 - 734.15 |
| 660.67 | 528.53 - 792.80 | ||
| 653.93 | 457.75 - 850.10 |
Overview of Jubilant Ingrevia Limited
ISIN
INE0BY001018
Industry
Biotechnology
Vol.Avg
363,792
Market Cap
107,506,805,443
Last Dividend
5
Official Website
IPO Date
2021-03-19
DCF Diff
N/A
DCF
0
Financial Ratios Every Investor Needs
Stock Dividend of JUBLINGREA
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-02-03 | February 03, 25 | 2.5 | 2.5 | 2025-02-03 | 2025-02-26 | |
| 2024-08-02 | August 02, 24 | 2.5 | 2.5 | 2024-08-02 | 2024-09-29 | |
| 2024-02-09 | February 09, 24 | 2.5 | 2.5 | 2024-02-09 | 2024-02-28 | |
| 2023-08-10 | August 10, 23 | 2.5 | 2.5 | 2023-08-10 | 2023-09-30 | |
| 2023-02-10 | February 10, 23 | 2.5 | 2.5 | 2023-02-10 | 2023-03-01 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 4,100.45 Cr | 3,183.85 Cr | 916.60 Cr | 0.2235 | 0.00 Cr | 387.04 Cr | 294.00 Cr | 182.89 Cr | 11.56 | 456.42 Cr | 0.0446 |
| 2023-03-31 | 4,740.48 Cr | 2,581.57 Cr | 2,158.91 Cr | 0.4554 | 25.30 Cr | 44.84 Cr | 444.10 Cr | 307.50 Cr | 19.34 | 580.51 Cr | 0.0649 |
| 2022-03-31 | 4,914.43 Cr | 2,958.48 Cr | 1,955.95 Cr | 0.3980 | 0.00 Cr | 45.82 Cr | 734.09 Cr | 476.71 Cr | 29.98 | 863.32 Cr | 0.0970 |
| 2021-03-31 | 678.97 Cr | 401.39 Cr | 277.58 Cr | 0.4088 | 0.00 Cr | 6.38 Cr | 98.40 Cr | 54.36 Cr | 20.77 | 106.78 Cr | 0.0801 |
| 2020-03-31 | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.0000 | 0.00 Cr | 0.00 Cr | -0.17 Cr | -0.17 Cr | -0.01 | -0.17 Cr | 0.0000 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 78.78 Cr | 4,731.89 Cr | 1,994.42 Cr | 2,737.4740 Cr | 740.24 Cr | 661.46 Cr | 964.81 Cr | 2,849.63 Cr | 11.46 Cr | 0.00 Cr | 15.49 Cr | 1,286.0760 Cr |
| 2023-03-31 | 72.73 Cr | 4,258.88 Cr | 1,592.65 Cr | 2,666.2300 Cr | 406.75 Cr | 334.02 Cr | 1,035.11 Cr | 2,356.90 Cr | 109.66 Cr | 216.13 Cr | 8.24 Cr | 1,179.5800 Cr |
| 2022-03-31 | 37.46 Cr | 3,797.15 Cr | 1,364.08 Cr | 2,433.0680 Cr | 237.84 Cr | 200.38 Cr | 911.16 Cr | 1,958.28 Cr | 101.42 Cr | 67.93 Cr | 6.19 Cr | 1,052.7780 Cr |
| 2021-03-31 | 73.34 Cr | 3,378.52 Cr | 1,455.58 Cr | 1,922.9390 Cr | 555.67 Cr | 482.33 Cr | 609.10 Cr | 1,857.16 Cr | 105.77 Cr | 525.28 Cr | 50.24 Cr | 894.3340 Cr |
| 2020-03-31 | 0.05 Cr | 0.05 Cr | 0.17 Cr | -0.1157 Cr | 0.00 Cr | -0.05 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.1657 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-03-31 | 429.9790 Cr | -569.5020 Cr | 144.1340 Cr | -138.3960 Cr | 6.0590 Cr | 78.7840 Cr | -568.3750 Cr | 267.6110 Cr | 336.2730 Cr | -78.6210 Cr | 93.0300 Cr |
| 2023-03-31 | 462.4600 Cr | -471.8900 Cr | 41.6000 Cr | -18.9300 Cr | 35.1200 Cr | 72.7300 Cr | -481.3900 Cr | 436.7100 Cr | 47.2540 Cr | -79.3130 Cr | -125.8400 Cr |
| 2022-03-31 | 452.7380 Cr | -71.8560 Cr | -417.7520 Cr | 222.5890 Cr | -35.7340 Cr | 37.6080 Cr | -230.1490 Cr | 708.9410 Cr | -318.7480 Cr | -45.1550 Cr | -304.9470 Cr |
| 2021-03-31 | 112.2810 Cr | -43.6550 Cr | -72.3650 Cr | 84.7360 Cr | 73.2920 Cr | 73.3420 Cr | -27.5450 Cr | 77.3870 Cr | -62.1880 Cr | 0.0000 Cr | -37.4140 Cr |
| 2020-03-31 | 0.3984 Cr | 0.0000 Cr | 0.0500 Cr | 0.3984 Cr | 0.4484 Cr | 0.0500 Cr | 0.0000 Cr | -0.1660 Cr | 0.0000 Cr | 0.0000 Cr | 0.0000 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2024-12-31 | 1,046.06 Cr | 538.63 Cr | 507.43 Cr | 0.4851 | 98.53 Cr | 69.38 Cr | 4.39 | 147.73 Cr | 0.0663 |
| 2024-09-30 | 1,045.24 Cr | 786.68 Cr | 258.56 Cr | 0.2474 | 84.97 Cr | 59.00 Cr | 3.73 | 134.89 Cr | 0.0564 |
| 2024-06-30 | 1,024.34 Cr | 786.88 Cr | 237.46 Cr | 0.2318 | 70.65 Cr | 48.74 Cr | 3.06 | 109.53 Cr | 0.0476 |
| 2024-03-31 | 1,074.44 Cr | 835.17 Cr | 239.27 Cr | 0.2227 | 55.52 Cr | 29.25 Cr | 1.85 | 100.74 Cr | 0.0272 |
| 2023-12-31 | 960.45 Cr | 508.60 Cr | 451.85 Cr | 0.4705 | 70.14 Cr | 38.56 Cr | 2.43 | 104.35 Cr | 0.0401 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2024-09-30 | 54.79 Cr | 57.78 Cr | 112.57 Cr | 0.00 Cr | 889.37 Cr | 1,778.65 Cr | 2,975.13 Cr | 4,841.29 Cr | 2,025.94 Cr |
| 2024-06-30 | -79.59 Cr | 159.18 Cr | 79.59 Cr | 0.00 Cr | 0.00 Cr | 79.59 Cr | 0.00 Cr | 0.00 Cr | -2,737.47 Cr |
| 2024-03-31 | 79.59 Cr | 36.89 Cr | 79.59 Cr | 571.97 Cr | 941.30 Cr | 1,779.90 Cr | 2,849.63 Cr | 4,731.89 Cr | 1,994.42 Cr |
| 2023-12-31 | -55.61 Cr | 111.22 Cr | 55.61 Cr | 0.00 Cr | 0.00 Cr | 55.61 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-09-30 | 46.96 Cr | 40.49 Cr | 87.45 Cr | 454.24 Cr | 1,049.56 Cr | 1,778.15 Cr | 2,572.47 Cr | 4,470.32 Cr | 1,770.38 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2024-06-30 | 48.74 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 29.25 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2023-12-31 | 38.56 Cr | 68.48 Cr | 0.00 Cr | 0.00 Cr | 68.48 Cr | 124.09 Cr | 55.61 Cr | 0.00 Cr | 68.48 Cr |
| 2023-09-30 | 57.49 Cr | 67.82 Cr | 0.00 Cr | 0.00 Cr | 67.82 Cr | 55.61 Cr | -12.21 Cr | 0.00 Cr | 67.82 Cr |
| 2023-06-30 | 57.59 Cr | 64.60 Cr | 0.00 Cr | 0.00 Cr | 64.60 Cr | 137.65 Cr | 73.05 Cr | 0.00 Cr | 64.60 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| No split history data available. | ||
Similar Stocks: Biotechnology
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Biocon Limited | BIOCON | ₹331.90 | ₹398,479,140,000.00 | ₹1,860,996.00 |
| Piramal Pharma Limited | PPLPHARMA | ₹220.76 | ₹292,672,172,632.00 | ₹3,206,567.00 |
| Syngene International Limited | SYNGENE | ₹724.60 | ₹290,777,127,354.00 | ₹309,960.00 |
| Concord Biotech Limited | CONCORDBIO | ₹1,712.30 | ₹179,134,319,260.00 | ₹167,947.00 |
| Blue Jet Healthcare Limited | BLUEJET | ₹742.40 | ₹128,780,727,808.00 | ₹402,801.00 |
| Jubilant Ingrevia Limited | JUBLINGREA | ₹674.95 | ₹107,506,805,443.00 | ₹165,388.00 |
| Supriya Lifescience Limited | SUPRIYA | ₹743.80 | ₹59,863,106,640.00 | ₹485,094.00 |
| Dishman Carbogen Amcis Limited | DCAL | ₹210.73 | ₹33,038,902,663.00 | ₹169,506.00 |
| Panacea Biotec Limited | PANACEABIO | ₹504.80 | ₹30,919,375,571.00 | ₹556,110.00 |
| Zota Health Care Limited | ZOTA | ₹884.35 | ₹24,657,917,174.00 | ₹61,116.00 |
Key Executives
Gender: male
Year Born:
Gender: female
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1977
Gender: male
Year Born: 1977
Gender: male
Year Born: 1966
Gender: female
Year Born: 1972
Gender: male
Year Born:
Gender: male
Year Born: 1956
Gender: male
Year Born: 1981
FAQs about Jubilant Ingrevia Limited
The CEO is Mr. Deepak Jain.
The current price is ₹674.95.
The range is ₹462.3-885.
The market capitalization is ₹10,750.68 crores.
The dividend yield is 0.74%.
The P/E ratio is 51.69.
The company operates in the Healthcare sector.
Overview of Jubilant Ingrevia Limited (ISIN: INE0BY001018) is a leading Biotechnology in India. With a market capitalization of ₹10,750.68 crores and an average daily volume of 363,792 shares, it operates in the Biotechnology. The company last declared a dividend of ₹5.